To determine whether hemoglobin E trait influences the antimalarial effect of artemisinin derivatives, we retrospectively compared 32 case patients with hemoglobin E trait to 32 control patients who did not have hemoglobin E, b-thalassemia, glucose-6-phosphate dehydrogenase deficiency, or a-thalassemia trait on the basis of a mean corpuscular volume у78 femtoliters. All patients were admitted to the Hospital for Tropical Diseases in Bangkok, Thailand, with acute falciparum malaria. Control patients were matched to case patients with hemoglobin E trait by treatment with artemisinin derivatives versus other antimalarial drugs, by ethnic group, and by parasite count. Among 38 patients treated with artemisinin derivatives, the presence of hemoglobin E trait was associated with significantly faster parasite clearance (2.9-fold; 95% confidence interval [CI], 1.4-6.3;
Hemoglobin E is common in the population of Thailand. For example, in a study of 2806 individuals in Phitsanulok, a province situated in the southern part of northern Thailand, the prevalence of hemoglobin E was 25% [1] , and among 985 neonates in Bangkok, hemoglobin E was present in 18.7% [2] . Erythrocytes from patients with hemoglobin E resemble bthalassemic erythrocytes; they have excess a-globin chains and increased amounts of hemoglobin degradative products that favor iron-mediated oxidative reactions [3, 4] .
Geographic overlap in the historical distributions of Plasmodium falciparum and hemoglobin E indicates that this hemoglobinopathy protects individuals against malarial infection. Studies in vitro have provided conflicting results regarding whether the presence of hemoglobin E trait inhibits the growth of intraerythrocytic malaria parasites [5, 6] . In a retrospective study of hospitalized patients, we found clinical evidence that hemoglobin E trait protects patients from severe complications associated with infection with P. falciparum [7] . Other investigators have found evidence that subjects with hemoglobin E trait who are on a fava-bean diet may enjoy protection from malaria [8] .
Artemisinin derivatives are important antimalarial drugs in Thailand, where P. falciparum that is resistant to other antimalarial drugs is highly prevalent. The artemisinins are endoperoxides that seem to exert their antiplasmodial action within parasitized red cells through oxidative reactions [4, 9] . Therefore, the presence of hemoglobin E trait might be expected to enhance the clinical antimalarial activity of artemisinin derivatives. To examine this possibility, we conducted a retrospective case-control study among patients with acute P. falciparum malaria who had been admitted to the Hospital for Tropical Diseases in Mahidol University, Bangkok, Thailand.
Materials and Methods
Selection criteria. We selected 32 case patients with acute P. falciparum malaria who had been admitted to the Hospital for Tropical Diseases from December 1990 to August 1997, who had hemoglobin E trait (based on hemoglobin electrophoresis) that demonstrated 20%-30% hemoglobin E and 70%-80% hemoglobin A, and who were negative for glucose-6-phosphate dehydrogenase (G6PD) deficiency. We selected 32 control patients who were negative for hemoglobin E, b-thalassemia, hemoglobin H, hemoglobin Constant Spring, and G6PD deficiency and in whom the mean corpuscular volume at the beginning of antimalarial treatment was у78 femtoliters (fL; suggesting the absence of a-thalassemia trait-deletion or abnormal expression of 2 of the 4 a-globin genes) [10, 11] . The control patients were matched to the case patients with hemoglobin E trait on the basis of treatment with artemisinin derivatives versus other agents and on the basis of ethnicity and initial parasite count. b-thalassemia trait was defined as a percentage of hemoglobin A 2 that was 14.5%, in accordance with the range of our laboratory. We were unable to identify a-thalassemia trait precisely, so we made a category of low mean corpuscular volume (!78 fL) at time zero in the absence of b-thalassamia and hemoglobin E. This category would include both a-thalassemia trait and iron deficiency (but probably mainly a-thalassemia). There are limitations to these methods of selection. We are unable to exclude the possibility that some of the hemoglobin E trait patients also had concomitant iron deficiency or a-thalassemia. Furthermore, our selection criteria for control patients cannot eliminate patients with a single a-globin gene abnormality or deletion.
Baseline studies. Age, sex, ethnic group, temperature (ºC), liver size, and spleen size at time zero were recorded. Hemoglobin electrophoresis, including quantification of hemoglobin E and hemoglobin A 2 , was performed by use of the cellulose acetate electrophoresis method [12] . This approach can screen for the common b-hemoglobinopathies and hemoglobin Constant Spring but not for the a-thalassemias. The fluorescent spot technique was used to screen for G6PD deficiency. A complete blood cell count, including hemoglobin, packed cell volume, mean corpuscular volume, white blood cell count, and platelets, was determined by use of an automated cell counter (Coulter T-890; Coulter, Hialeah, FL). Serum concentrations of total bilirubin, creatinine, and blood urea nitrogen were measured with an automated serum chemistry analyzer (Technicon RA-2000; Miles, Tarrytown, NY). The direct bilirubin was determined by the method of Malloy and Evelyn [13] , and the indirect bilirubin was derived by subtracting the direct bilirubin from the total bilirubin. Thick and thin blood films were stained with Giemsa stain, and the parasite counts were determined by counting the number of asexual parasites per 200 white blood cells or 1000 red blood cells and expressing the results in counts per microliter.
Treatment and follow-up. All patients received antimalarial drug therapy as part of clinical trials. They were treated with one of the following treatment regimens: (1) an artemisinin derivative ( ), (2) mefloquine with or without tetracyline or doxycycline n = 38 ( ), or (3) quinine with or without tetracycline ( ). The n = 15 n = 11 artemisinin derivatives were dihydroartemisinin in 19 patients, artesunate in 10 patients, arteether in 8 patients, and artemether in 1 patient. The artemisinin derivatives were given as single agents except in 2 patients, one of whom received mefloquine in addition to artemether and the other of whom received primaquine in addition to artesunate. The median (range) parasite clearance times were 44 h (18-88 h) with artemisinin derivatives, 62 h (34-98 h) with mefloquine, and 87 h (48-116 h) with quinine.
Thick and thin blood films were prepared (every 6 h) to determine parasite counts until 3 films were negative. Blood films were considered negative after examination of 200 oil-immersion fields showed no asexual parasites. Thereafter, blood films were prepared daily. Parasite clearance times were calculated from the initiation of antimalarial treatment until the first time that peripheral blood films were negative for asexual parasites. Temperatures were recorded every 6 h. Fever clearance times were calculated from the initiation of treatment until the body temperature had decreased to !37.5ЊC and until it remained at !37.5ЊC for at least 24 h.
Statistical methods. Baseline variables were compared between the hemoglobin E trait group and the control patients by use of the 2-sample t test for continuous variables which followed a Gaussian distribution, the nonparametric Kruskal-Wallis test for variables which did not follow a Gaussian distribution, and the Fisher's exact test for proportions. Cox proportional hazards models were used to compare parasite clearance times and fever clearance times between the 2 study groups, with adjustments for the type of antimalarial treatment, the logarithm of the parasite count at time zero, and the ethnic group. In subgroup analyses, parasite clearance times were compared according to presence or absence of hemo- globin E trait in the patients treated with artemisinin derivatives and in the patients treated with other antimalarial drugs.
Results
The presenting demographic and clinical features are shown in table 1. Compared with control patients, case patients with hemoglobin E trait had significantly lower mean corpuscular volumes.
As shown in table 2, the presence of hemoglobin E trait was associated with a significantly faster estimated parasite clearance during antimalarial therapy (hazards ratio, 1.9; 95% confidence interval [CI], 1.1-3.2;
). Subgroup analyses re-P = .027 vealed that this effect occurred exclusively in the patients who were treated with artemisinin derivatives. Among the patients treated with artemisinin derivatives, hemoglobin E trait was associated with an estimated 2.9-fold increase in parasite clearance rate (95% CI, 1.4-6.3;
). Among patients treated P = .006 with other antimalarial drugs only, the increase in estimated parasite clearance rate with hemoglobin E trait was not statistically significant (1.1-fold; 95% CI, 0.5-2.5;
). P = .8 Fever clearance times were not significantly different between case patients with hemoglobin E trait and control patients (data not shown).
Discussion
Our clinical study is limited because the data were examined retrospectively and because the sample size was small. Nevertheless, our results suggest that hemoglobin E trait may potentiate the antimalarial effect of artemisinin derivatives in the clinical setting.
Several possible explanations for the apparent potentiating effect of hemoglobin E trait on parasite clearance by artemisinin derivatives can be offered. One explanation is that increased amounts of hemoglobin degradative products and precipitated a-globin chains favor iron-mediated oxidative reactions in the parasitized hemoglobin E trait erythrocytes [4, 9] and that these oxidative reactions potentiate the parasite-toxic action of artemisinin derivatives. Another possible explanation is a difference in the pharmacokinetics of artemisinins between individuals with hemoglobin E trait and individuals with normal hemoglobins. Although such a difference has not been reported for hemoglobin E trait, a pharmacokinetic study indicated that plasma concentrations of artesunate and area under the concentration time curves are significantly higher in patients with certain a-thalassemias (hemoglobin H disease and hemoglobin Constant Spring), compared with these measures in patients with normal hemoglobins [14] .
The present observations are in contrast to in vitro experimental data, which indicate that the antimalarial effect of artemisinin derivatives is diminished in the presence of hemoglobin H or hemoglobin Constant Spring [15, 16] . This effect in vitro appears to be attributable to decreased accumulation of artemisinin derivatives within parasitized, compared with nonparasitized, a-thalassemic erythrocytes. Several reasons may explain the disparate results between our present clinical study with hemoglobin E trait and the previous studies with a-thalassemic conditions in vitro. First, hemoglobin H and hemoglobin Constant Spring are characterized by an excess accumulation of b-globin chains in the erythrocyte cytoplasm, whereas hemoglobin E trait is characterized by an excess accumulation of a-globin chains. The difference in the types of these excess globin chains might influence their oxidative potential and the degree of any changes in permeability that are induced in variant erythrocyte membranes. Second, immune responses are an additional factor in the patient compared with the erythrocyte culture. It is possible that a heightened sensitivity of parasitized variant erythrocytes to immune responses in the presence of artemisinin derivatives might outweigh a reduced accumulation of the drug within these erythrocytes. Third, if the described altered pharmacokinetics of artemisinin derivatives in patients with hemoglobin H disease and hemoglobin Constant Spring [14] apply to patients with hemoglobin E trait, there might be an enhanced antimalarial effect of artemisinin derivatives in patients with hemoglobin E trait (related to higher drug levels).
On the basis of the findings of this study, prospective investigations into the influence of hemoglobin E trait and other hemoglobinopathies and thalassemias on the antimalarial effect of the artemisinin derivatives may be indicated. The present results raise the intriguing possibility that antimalarial therapy, in the future, might be tailored to an individual's type of hemoglobin.
